WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a new license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the technology underlying its Pin-point™ base editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback